BeOne has been recognized by U.S. News & World Report as one of the Best Companies to Work For. This recognition affirms our belief that our greatest strength is our people – over 12,000 strong across six continents – united by science, driven by purpose, and relentless in our focus on patients. Learn more: https://lnkd.in/df6DJ8Yy #TeamBeOne #BeOneAgainstCancer #CompanyCulture
BeOne Medicines
Pharmaceutical Manufacturing
Cambridge, Massachusetts 254,623 followers
Cancer has no borders. Neither do we.
About us
BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram. We all share the responsibility to report adverse events observed with our products so that they may be investigated, actioned, and communicated accordingly. To report an adverse event or side effect, please talk to your healthcare provider and contact us here: https://beonemedicines.com/contact-us/report-adverse-event/.
- Website
-
www.beonemedicines.com
External link for BeOne Medicines
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Founded
- 2010
- Specialties
- oncology, hematology, cancer treatment, solid tumor, and targeted therapy
Locations
Employees at BeOne Medicines
Updates
-
#News for #Investors and #Media: BeOne announces positive topline results from a Phase 3 study evaluating our foundational BTK inhibitor in combination with rituximab versus standard chemoimmunotherapy in previously untreated adult mantle cell lymphoma (#MCL) patients. This is the first study of its kind to demonstrate superiority of a BTK inhibitor-based, chemotherapy-free regimen in this patient population. Read the full announcement: https://lnkd.in/dB_mex7E #Oncology #MCL #BeOneInnovator
-
-
BeOne Medicines reposted this
A week ago, Eloy Room conceded seven goals to Germany. This weekend, he made save after save against Ecuador — tying the World Cup saves record set by our partner Tim Howard in 2014 — and earning Curaçao their first World Cup point in history. Room said he thinks Tim was “sweating in front of the TV because I was close.” Knowing Tim Howard and having talked to him about this exact scenario a few months ago, I am confident he was actually cheering on his fellow goalkeeper. That comeback, that performance, that point for a tiny Caribbean nation — that’s what One Save Changes Everything was built to celebrate. A single moment can redefine outcomes, inspire teams, and elevate entire nations. For Curaçao, that point represents more than a statistic; it represents what is possible when you refuse to give up. Congratulations, Eloy. BeOneSave.com #TeamBeOne
-
At BeOne, we believe no one should face cancer alone. We're honored to announce an expanded, first-of-its-kind partnership with Blood Cancer United — a three-year commitment to provide more patients and families with trusted education, personalized support, and community programs that help them navigate every step of the blood cancer journey. Together, we are how the world stops cancer. Learn more: https://lnkd.in/epDPk3Z8 #BeOneAgainstCancer #PatientsFirst
-
-
A great save is about more than one moment. It’s hope. Resilience. Purpose. This summer, the world will celebrate every great save on the field. At BeOne, that same drive fuels our commitment to advancing cancer care every day. Learn more: https://bit.ly/49UrgJV
What Does a Save Mean to You?
-
BCL-2 dependence is a key driver of tumour-cell survival across hematologic malignancies. But the full potential of BCL-2 inhibition has yet to be realised. Explore how BeOne is evaluating advancements in BCL-2 inhibition as a potential backbone of treatment across hematologic malignancies. Visit www.bcl2i.com. Intended for healthcare professionals only.
-
Tack, Stockholm. As #EHA2026 comes to a close, we leave inspired by the conversations and scientific momentum shared across the global hematology community. This week brought together bold science and a shared determination to advance care for patients with blood cancers. Throughout the congress, one thing was clear: innovation moves faster when the global oncology community works together. Thank you to everyone who visited our booth, joined our sessions, and connected with our team throughout the week. If you missed us, explore our latest data and congress highlights here: https://lnkd.in/gqumyPDr #TeamBeOne
-
-
At #EHA2026, we're sharing updates on our BTK degrader, currently the most advanced in clinical development. Hear from our Chief Medical Officer Amit Agarwal, M.D., Ph.D., on what this new data in relapsed/refractory CLL means for patients who need different treatment options. Learn more about BeOne at EHA: https://lnkd.in/gqumyPDr #FromFloorToFeed #TeamBeOne
-
At #EHA2026, we’re highlighting new long-term data in a CLL population that has often been underrepresented in clinical trials: patients aged 80 and older. Hear from Dany Habr, M.D., our Head of Medical Affairs, North America & International Markets, on why this data helps address an important evidence gap for the patients clinicians treat every day. Learn more about BeOne at EHA: https://lnkd.in/gqumyPDr #FromFloorToFeed #TeamBeOne
-
#News for #Investors and #Media: This weekend at #EHA2026, we’re presenting updated data evaluating our BTK degrader in patients with CLL/SLL. Resistance and relapse remain persistent challenges for many patients with CLL/SLL, underscoring the need for continued innovation across B-cell malignancies. The data reflects the momentum of our expanding hematology portfolio and our commitment to moving with speed, scientific rigor, and purpose as we work to deliver new possibilities for patients. Explore the data here: https://lnkd.in/dXJDifBh #BeOneInnovator
-